Navigation Links
Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and,Effective in Colorectal Cancer with Liver Metastases

ins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We have licensed our lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide. We have retained the rights for epratuzumab in oncology indications for which UCB has been granted a buy-in option. UCB has development, manufacture and commercialization rights, and is responsible for all clinical trials evaluating epratuzumab for the treatment of patients with moderate and severe lupus. At present, there is no cure for lupus and no new lupus drug has been approved in the U.S. in the last 40 years. The Company is conducting clinical trials with hA20 in patients with non-Hodgkin's lymphoma, epratuzumab as a potential therapeutic for patients with lymphoma and leukemia, 90Y-epratuzumab for the therapy of patients with lymphoma, 90Y-hPAM4 for pancreas cancer therapy and hCD74 as a therapy for patients with multiple myeloma. We believe that our portfolio of intellectual property, which includes approximately 108 patents issued in the United States, and more than 250 other issued patents worldwide, protects our product candidates and technologies. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock and Lock (DNL) methodology, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. For additional information on us, please visit our web site at http://www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward- looking statements made pursuant to the Pri
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Fractionated Radioimmunotherapy With (90)Y-epratuzumab in Non-Hodgkins Lymphoma Appears Safe and Active in a Phase I/II Study
2. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
3. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
4. Merck at ASCO 2007: New Data Demonstrate the Value of UFT as an Important Treatment Option for Patients With Metastatic Colorectal Cancer
5. Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer
6. The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer
7. Poniard Pharmaceuticals Announces Promising Data From Interim Safety Analysis of Phase 1 Combination Trials of Picoplatin in Colorectal and Prostate Cancers
8. Positive Final Data from HyCAMP Phase II Trial in Metastatic Colorectal
9. Final Vectibix Positive Pivotal Phase 3 Trial Results In Metastatic Colorectal Cancer Patients Published
10. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
11. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
Post Your Comments:
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
(Date:5/21/2015)... 2015 Research and ... addition of the "North American Joint ... Replacement, Elbow Replacement, Hip Replacement, Knee Replacement, ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... valued at $4,470.9 million in 2014 and ...
(Date:5/21/2015)... ATLANTA , May 21, 2015  CryoLife, Inc. ... tissue processing company focused on cardiac and vascular surgery, ... a quarterly cash dividend for the second quarter 2015 ... quarterly cash dividend of $0.03 per share will be ... of record as of June 12, 2015.  The ex-dividend ...
Breaking Medicine Technology:Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2CryoLife Announces Quarterly Cash Dividend for the Second Quarter 2015 2
... inception in 2007, the world’s leading medical technology ... this year’s conference was no exception. Compared with ... up nearly 12 percent, CEO-level participation rose five ... fifth annual conference also drew attendees from 22 ...
... Oct. 5, 2011 myMatrixx®, a full-service pharmacy and ... today that Phil Walls, R.Ph., Chief Clinical & Compliance ... awards programs. The first is Health Care Heroes hosted ... is a finalist in the Medical Professional Non-Physician category. ...
Cached Medicine Technology:Annual AdvaMed MedTech Conference Continues Impressive Growth 2Annual AdvaMed MedTech Conference Continues Impressive Growth 3myMatrixx's Phil Walls, R.Ph. Receives National and Regional Recognition 2
(Date:5/23/2015)... FL (PRWEB) May 23, 2015 On Saturday, ... build a new playground for Branches Florida City exactly five ... former play space in 2010. , A large fire tore ... playground on May 23, 2010 in the middle of the ... The fire was later declared arson even though it is ...
(Date:5/23/2015)... York, NY (PRWEB) May 23, 2015 ... announced that, “the company has been the target ... as a part of the company’s ongoing Information Technology ... on health insurers.” , The most notable attack ... year when Anthem Inc., the nation’s second largest health ...
(Date:5/23/2015)... Javon Bea Mercy Health System CEO ... Center, 557 N. Washington St., Janesville, will host an ... pm. , The 8-week clinic is lead by Brent ... who will offer training that encompasses a warm-up, training ... show selection and weekly training plans. , The program ...
(Date:5/22/2015)... Pioneer Millworks, the largest reclaimed wood company in ... reclaimed wood, introducing their latest reclaimed wood products at ... offerings, Vat 35, Reclaimed Teak , and Prairie ... largest design event. , “Designers, architects, builders, and homeowners ... see and feel the variety of wood surfaces in ...
(Date:5/22/2015)... 22, 2015 Hundreds of federal ... of individuals who allegedly experienced serious internal bleeding ... to move forward in the U.S. District Court, ... Order dated May 4, 2015, the Court has ... electronically stored information. Among other things, the Order ...
Breaking Medicine News(10 mins):Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 2Health News:One Headline Making Cyber Attack Sparks Discovery of Another 3Health News:One Headline Making Cyber Attack Sparks Discovery of Another 4Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4
... In a research study appearing in the journal ... Harbor Laboratory (CSHL) and four other institutions have identified a ... has limited treatment options and one of the worst one-year ... that up to 15% of liver tumors are "driven" by ...
... Mutations in three pathways important for suppressing tumors ... that strikes children and adults. But new research ... those changes alone are not sufficient to cause ... different points in the same disrupted regulatory pathways. ...
... Spanish . The Hospital Clnic of Barcelona presented today ... Felipe Garcia and Dr. Agata Len , from the Hospital ... Gatell . The tool has been created by a team from the ... and Csar Cceres . Through a direct connection via a webcam, ...
... Researchers at Georgia Health Sciences University are studying whether ... metabolite could halt the progression of diabetic nephropathy, or ... year, $308,000 grant from the American Heart Association, Dr. ... College of Dental Medicine and Pharmacology and Toxicology in ...
... the brain transmits messages to other parts of the ... dementia, multiple sclerosis and stroke. Scientists at the ... maintaining the health and function of the segment of ... brain. The study, published in the journal ...
... U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Stony ... a "wearable," portable PET scanner they,ve developed for rats. ... simultaneously studying brain function and behavior in fully awake, ... validation studies in the April 2011 issue of Nature ...
Cached Medicine News:Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 2Health News:Study identifies therapeutic target for liver cancer and predictive biomarker of response 3Health News:Key mutations act cooperatively to fuel aggressive brain tumor 2Health News:Key mutations act cooperatively to fuel aggressive brain tumor 3Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 2Health News:Virtual assistance is confirmed as an effective tool in monitoring HIV patients 3Health News:Miniature 'wearable' PET scanner ready for use 2Health News:Miniature 'wearable' PET scanner ready for use 3Health News:Miniature 'wearable' PET scanner ready for use 4
... BacT/Alert 3D Signature is a state ... system that integrates blood, sterile body ... a powerful microbiology workstation with comprehensive ... volume identification and where expanded flexibility ...
... 3D Select is a state ... detection system that integrates blood, ... culturing. This system is useful ... laboratory information system (LIS) connectivity ...
The Vitek 2 - XL is a fully automated bacteriology system that performs bacterial identification and susceptibility testing analysis using a standard inoculum. It detects resistance and helps combat ...
IDS Rapid ANA II System, a microbial identification system....
Medicine Products: